Similar articles

• The childhood AML studies BFM-78 and -83: treatment results and risk factor analysis.

  Creutzig U, Ritter J, Riehm H, Budde M, Schellong G. Creutzig U, et al. Haematol Blood Transfus. 1987;30:71-5. doi: 10.1007/978-3-642-71213-5_12. Haematol Blood Transfus. 1987. PMID: 3305225 Clinical Trial. No abstract available.
• Improved treatment results in the myelocytic subtypes FAB M1-M4 but not in FAB M5 after intensification of induction therapy: results of the German childhood AML studies BFM-78 and BFM-83.

  Ritter J, Creutzig U, Schellong G. Ritter J, et al. Haematol Blood Transfus. 1990;33:185-92. doi: 10.1007/978-3-642-74643-7_35. Haematol Blood Transfus. 1990. PMID: 2182410 Clinical Trial. No abstract available.
• [Treatment of recurrence of acute myeloid leukemia in childhood. A retrospective analysis of recurrence in the AML-BFM-83 study].

  Stahnke K, Ritter J, Schellong G, Beck JD, Kabisch H, Lampert F, Creutzig U. Stahnke K, et al. Klin Padiatr. 1992 Jul-Aug;204(4):253-7. doi: 10.1055/s-2007-1025356. Klin Padiatr. 1992. PMID: 1518261 Clinical Trial. German.
• [Hematologic tumors].

  Ogawa M. Ogawa M. Gan To Kagaku Ryoho. 2003 Oct;30(10):1416-21. Gan To Kagaku Ryoho. 2003. PMID: 14584273 Review. Japanese.
• Development of a curative treatment within the AML-BFM studies.

  Creutzig U, Zimmermann M, Dworzak MN, Ritter J, Schellong G, Reinhardt D. Creutzig U, et al. Klin Padiatr. 2013 May;225 Suppl 1:S79-86. doi: 10.1055/s-0033-1337968. Epub 2013 May 22. Klin Padiatr. 2013. PMID: 23700063 Review.